

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/716,810	11	/19/2003	Michael R.S. Hill	P-9092-04 7000	
27581	7590	03/15/2006		EXAMINER	
MEDTRON	•		LAYNO, CARL HERNANDZ		
710 MEDTRONIC PARK MINNEAPOLIS, MN 55432-9924				ART UNIT	PAPER NUMBER
				3766	

DATE MAILED: 03/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

				E .			
		Application No.	Applicant(s)				
Office Action Summary		10/716,810	HILL ET AL.				
		Examiner	Art Unit				
		Carl H. Layno	3766				
Period fo	The MAILING DATE of this communication app or Reply	pears on the cover sheet with the	correspondence address				
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.11 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period or to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ti will apply and will expire SIX (6) MONTHS fror , cause the application to become ABANDON	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).				
Status							
1)⊠	Responsive to communication(s) filed on 17 Ja	anuary 2006.					
2a) <u></u> ☐	This action is FINAL . 2b)⊠ This action is non-final.						
3)	• • • • • • • • • • • • • • • • • • • •						
	closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposit	ion of Claims						
5)⊠ 6)⊠ 7)⊠	Claim(s) 3-16,19-30 and 34-49 is/are pending 4a) Of the above claim(s) is/are withdraw Claim(s) 3-16,19-25,34 and 35 is/are allowed. Claim(s) 26-28,36-38 and 40-45 is/are rejected Claim(s) 29,30,39 and 46-49 is/are objected to Claim(s) are subject to restriction and/o	wn from consideration. d.					
Applicat	ion Papers						
10)⊠	The specification is objected to by the Examine The drawing(s) filed on <u>19 November 2003</u> is/a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	re: a)⊠ accepted or b)⊡ object drawing(s) be held in abeyance. Se tion is required if the drawing(s) is o	ee 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).				
Priority (under 35 U.S.C. § 119						
12)[a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau See the attached detailed Office action for a list	s have been received. s have been received in Applica rity documents have been receiv u (PCT Rule 17.2(a)).	tion No ed in this National Stage				
Attachmen	et(s) te of References Cited (PTO-892)	4) 🔲 Interview Summar	y (PTO-413)				
2) Notice 3) Information	ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) er No(s)/Mail Date	Paper No(s)/Mail [

DETAILED ACTION

1. Acknowledgment is made of applicant's amendment, which was received by the Office on January 17, 2006.

2. Claims 1, 2, 17, 18, and 31-33 have been canceled. Claims 3-16, 19-30, and 34-49 are active.

Claim Rejections - 35 USC § 102/103

- 3. In view of applicant's claim cancellations, the Examiner is withdrawing the 35 U.S.C 102(b)/103(a) rejections based upon the Mackey '877 and Elsberry et al '689 patents, which were made against claims 1, 2, 17, 18, and 31-33 in the last Office action.
- 4. However, upon further consideration, a new ground(s) of rejection is made in view of the Hartlaub (US 6,134,470) and Cammilli et al (US 6,167,305) patents.
- 5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

6. Claims 26-28, 36-38, and 40-44 are rejected under 35 U.S.C. 102(e) as being anticipated by Hartlaub (US 6,134,470).

The applied reference has a common assignee with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

In regard to claim 26, the Hartlaub (US 6,134,470) patent describes an apparatus for treating a tachyarrhythmic patient (Figs. 1 and 2) using electrical stimulation. The device (Fig.2) comprises a microprocessor 224, spinal cord stimulation electrodes (330,332,334,336), and cardiac stimulation electrodes (317,321,324,326,310,311,320,318). In use, the spinal cord stimulation is activated in response to a detected arrhythmia. The device then senses whether or not the arrhythmia has been terminated. If not, anti-tachycardia pacing therapy may be delivered (col.12, lines 3-8).

Application/Control Number: 10/716,810

Art Unit: 3766

In regard to claim 27, the spinal cord stimulation electrodes are considered to be "metal" and are quadripolar in-line assemblies in Medtronic[™] Model 3487A or 3888 leads (col.4, lines 41-50).

In regard to claim 28, the cardiac leads appear to be defibrillation leads with cardiac pacing electrodes (Figs.1 and 2), among them a "screw-in" electrode 166 (Fig.1) and bipolar electrodes (317,321,324,326 – Fig.2).

In regard to claim 36, the device could conceivably use spinal cord stimulation (SCS) in combination with pacing (or defibrillation) therapy to treat an arrhythmia (col.12, liens 3-8). The spinal cord stimulation treatment would stop when the device senses that tachyarrhythmia is no longer present and a normal sinus rhythm (NSR) has begun (Fig.4 – block 422).

In regard to claims 37, 38, and 40, the Hartlaub stimulator may be equipped with an implantable drug pump (Abstract, lines 20-22 and col.5, lines 3-13) for delivering "antitachyarrhythmia drugs". These drugs would, in all likelihood, be produced synthetically (i.e. manufactured).

In regard to claim 41, the spinal cord stimulation lead **124** is placed in the intrathecal or epidural space (Fig.3). See col.4, lines 44-46.

In regard to claim 42, the spinal cord stimulator may be employed for treating chronic pain (col.13, lines 15-23).

In regard to claims 43 and 44, depending upon the presence or absence of tachyarrhythmias, cardiac and nerve stimulation will be active; hence, intermittent operation.

7. Claims 36, 37, 42, and 45 are rejected under 35 U.S.C. 102(e) as being anticipated by Cammilli et al (US 6,167,305).

The Cammilli et al (US 6,617,305) patent describes an implantable defibrillation system (Fig.1), which uses a spinal cord nerve stimulator C as an analgesic prior to and during stimulation by a shock generator E (Abstract).

In regard to claims 37 and 42, the device may, alternatively, be equipped with a drug infusion pump for administering an analgesic (col.4, lines 15-21).

Allowable Subject Matter

- 8. Claims 29, 30, 39, and 46-49 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- 9. Claims 3-16, 19-25, 34, and 35 are allowed.

Conclusion

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carl H. Layno whose telephone number is (571) 272-4949. The examiner can normally be reached on 9/4/5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert E. Pezzuto can be reached on (571) 272-6996. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3766

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CARL LAYNO
PRIMARY EXAMINER

Carl H. Lagro

CHL 3/10/2006